Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
DESCRIPTION (Adapted from the Investigator's Abstract): Exposure to
toxins and chemicals, including drugs, can produce aberrant immune
reactions which may include autoimmunity. The observation which
continues to elude explanation in chemical-induced autoimmunity is the
restriction of autoantibody responses to a single, or a limited number
of intracellular antigens, the specificity of which appears dependent
in part upon the chemical involved. The investigator has shown that the
heavy metal mercury induces a genetically restricted autoantibody
response in mice that predominantly targets the nucleolar protein
fibrillarin. This murine autoantibody response bears remarkable
similarity to the anti-fibrillarin response in human scleroderma.
Although the investigator's preliminary studies show that interaction of
viable cells or isolated nuclei with mercuric chloride leads to
modification of the molecular properties of fibrillarin, anti-
fibrillarin autoantibodies do not appear to be directed against a
fibrillarin-mercury complex. This suggests that mercury modification of
fibrillarin may influence antigen processing of T cell responses
associated with anti-fibrillarin autoantibody production. This is
supported by additional preliminary studies showing that mercury causes
apoptotic-like cell death in macrophages which is associated with
proteolytic activity. Preliminary studies show that addition of
exogenous fibrillarin to lysates from HgCl2 killed, but not untreated
(control) macrophages results in proteolytic cleavage of the protein.
This proteolytic activity is inhibited by serine protease inhibitors,
showing it to be unrelated to apoptosis cysteine proteases of the
ICE/CED-3 family. It is the aim of this proposal to test the hypothesis
that this combination of interaction with mercury and digestion by
protease leads to enhanced immunogenicity of fibrillarin, which
stimulates autoreactivity among T and B cells and autoantibody production
in mice of the appropriate H-2 genotype. Mercury modification of
fibrillarin will be examined by mutation of the fibrillarin sequence to
determine the residues responsible for the observed change in the
molecular properties of fibrillarin upon interaction with mercury.
Purified wild type and mutated fibrillarin, in the presence and absence
of mercury, will be tested for their ability to elicit T cell and B cell
responses to determine if mercury modified fibrillarin is sufficient to
elicit an autoimmune response with properties similar to that produced
by mercury in vivo. The significance of the protease digestion of
fibrillarin in the autoimmune response will be determined by isolation
of the protease to allow examination of the expression and cellular
localization of the protease. The protease will also be used for the
digestion of wild type and mutated fibrillarin to examine the potential
of proteolytic fragments to stimulate T and B cells from mice sensitive
and resistant to mercury-induced autoimmunity. By analyzing the ability
of mercury modified fibrillarin to interact with cells of the lymphoid
system insights might be gained as to how an immunotoxin renders a self
antigen immunogenic. Such observations may be of significance in
understanding immunotoxicity of other heavy metals and xenobiotics in
general.
National Institute of Environmental Health Sciences
CFDA Code
DUNS Number
781613492
UEI
PHZJFZ32NKH4
Project Start Date
01-August-1996
Project End Date
31-July-1999
Budget Start Date
01-August-1997
Budget End Date
31-July-1998
Project Funding Information for 1997
Total Funding
$188,183
Direct Costs
$107,533
Indirect Costs
$80,650
Year
Funding IC
FY Total Cost by IC
1997
National Institute of Environmental Health Sciences
$188,183
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01ES008080-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01ES008080-02
Patents
No Patents information available for 5R01ES008080-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01ES008080-02
Clinical Studies
No Clinical Studies information available for 5R01ES008080-02
News and More
Related News Releases
No news release information available for 5R01ES008080-02
History
No Historical information available for 5R01ES008080-02
Similar Projects
No Similar Projects information available for 5R01ES008080-02